Can a Negative Urine THC Screen Exclude Exposure After a CBD-Labeled Product? Five Emergency Cases

Short answer: No. In a five-patient emergency-department case series from Japan, one patient had a negative bedside urine cannabinoid screen while a separately collected serum specimen contained measured THC-COOH. Two other patients screened positive, and the remaining two screened negative. This is not proof that urine testing is unreliable in every circumstance: the study did not report a simultaneous quantitative urine THC-COOH result for the patient with the negative screen and positive serum finding. It demonstrates why the tested matrix, test method, collection time, and target analyte must be identified before interpreting a negative result.

The original report is Maki Y, Tsuchiya A, Yamamoto R, Saito T, Morita S, and Nakagawa Y (2024), Safety of cannabidiol products as a social issue: A case series, Acute Medicine & Surgery 11:e965, doi:10.1002/ams2.965. The original dataset consists of five patients, not a diagnostic-accuracy trial, a population survey, or a controlled experiment administering chemically authenticated pure CBD.

What question can this emergency case series actually answer?

The narrow evidentiary question is whether a qualitative urine test performed during emergency evaluation necessarily excludes exposure to cannabinoids when the patient’s history involves a product sold or described as CBD. Maki and colleagues documented five ambulance presentations in 2023 following gummies or inhaled e-cigarette liquids. Symptoms included nausea, vomiting, agitation, breathing complaints, and altered responsiveness. The researchers supplied a clinical case narrative and a table combining bedside urine screening, serum THC-COOH, and selected urine THC-COOH results.

Because these were clinical presentations, the case series is especially useful for spotting unwarranted changes in the question being answered. A product label is not independent chemical verification. A qualitative screen is not a measured concentration. A serum metabolite result is not a venous whole-blood concentration of active THC. Clinical symptoms are not a standardized driving test. A temporal sequence after use cannot, by itself, identify the ingredient or mechanism that caused the symptoms.

The case series can support careful differential testing and case-record review. It cannot establish the incidence of contamination in CBD products, validate a screening device’s sensitivity, identify an exposure-to-symptom dose-response curve, or set a blood concentration for impairment.

Which five patients were examined, and which specimens were available?

All five patients were adults aged 18–36. Two reported gummy use or were exposed to e-cigarette products described as CBD; the individual case narratives distinguish three products with pictured ingredient information from the e-cigarette used in Cases 4 and 5, which was not brought to the hospital for examination. The source table lists five DS10 urine screen outcomes. Serum THC-COOH was reported for four people, and laboratory urine THC-COOH for three. These changing denominators matter.

These numerical serum results were reported by the authors as THC-COOH in serum, ng/mL. They are not THC measurements. The original table reports no serum specimen from Case 1 and no urine sample for quantitative THC-COOH from Cases 1 or 2. The original article does not establish that all five patients supplied comparable serum and urine specimens collected at the same elapsed time.

How many screening results were negative and how many serum metabolites were detected?

The DS10 screening column was negative for Cases 1, 2, and 4, and positive for Cases 3 and 5: three negative and two positive among five screened. A separate serum THC-COOH entry was detected in Cases 2, 3, and 5, not detected in Case 4, and unavailable in Case 1: three detected among four serum results. The independent urine THC-COOH entries were positive in Cases 3 and 5 and not detected in Case 4: two detected among three urine analytical entries.

Those fractions are descriptive, not population estimates. None should be described as clinical sensitivity, specificity, positive predictive value, or the false-negative percentage of DS10. The patients were selected because of medical presentations, different specimens were missing for different reasons, and the paper does not provide a validated reference-standard comparison for every screening episode.

What does the negative DS10 result in Case 2 actually mean?

Case 2 was a 20-year-old man who reported inhalation of a CBD-labeled e-cigarette approximately one hour before a car ride. He was described as becoming unresponsive while a passenger. The DS10 urine screen was negative; laboratory analysis of serum on the first day reported THC-COOH at 5.5 ng/mL. He had vomiting and was hospitalized for four days. This is the clearest between-matrix discordance in the series.

It is important not to rewrite it into a stronger statement: the publication did not supply a quantitative urine THC-COOH concentration from Case 2. Thus a negative bedside screen and positive serum metabolite are not two contradictory measurements made on the same urine specimen. They reflect different matrices and may have different targets, detection limits, sensitivity, processing, and elapsed times. The paper does not specify the complete DS10 validation, threshold, sample-collection chronology, or paired analytical laboratory protocol needed to isolate which difference caused the result.

The authors considered early screening a possible explanation. That is a reasonable question to investigate, not a demonstrated diagnosis of why this particular result was negative. An analytical reviewer would seek the exact specimen timestamps and method documentation rather than assert that every urine screen becomes positive after a fixed number of hours.

Why is serum THC-COOH different from active THC in forensic whole blood?

THC-COOH is an oxidative cannabinoid metabolite. Its detection can support a history of cannabinoid exposure within the assay’s validated specificity, but it is not the same molecule as active delta-9-THC. Serum is the liquid fraction remaining after clotting; it is not directly interchangeable with the original whole-blood volume used in some forensic drug-driving statutes or casework. The article’s serum values cannot be relabeled as whole-blood THC concentrations or converted into a driving threshold by assumption.

Nor does a urine THC-COOH number represent a concurrent circulating psychoactive dose. Renal excretion, urine dilution, timing, and test cutoffs can affect what is observed. Even if a properly identified THC-COOH result confirms exposure, it does not locate the exact ingestion moment or quantify contemporaneous psychomotor effects. For a matrix-based framework, the site’s published guide to biological matrices explains why specimen selection is inseparable from interpretation.

Case 2’s 5.5 ng/mL serum THC-COOH is therefore not a 5.5 ng/mL whole-blood THC finding. The same separation applies to the 9.2 ng/mL serum value in Case 3 and the 10.8 ng/mL serum value in Case 5. Nothing in the series determines a particular person’s active THC level at the time of a motor vehicle event.

Were the products proven to contain delta-9-THC?

The authors described cannabinoid or THC-like constituents in the products associated with Cases 1–3, and their Figure 1 depicts a gummy product and an e-cigarette package alongside component listings. The lists include compounds such as HHCP, H4CBD, THCV, CBDV, CBG, and CBD for particular products. These names are not all interchangeable with delta-9-THC. A product carrying cannabinoid-analogue ingredients is not automatically a laboratory-confirmed delta-9-THC formulation.

The paper does not provide an individual batch’s comprehensive validated quantitative composition, original chain of custody, analytical uncertainty, complete mass-spectral characterization, or measured absorbed cannabinoid dose. Cases 4 and 5 had no product brought in for comparable direct evaluation. The source’s general wording about THC components should therefore be interpreted alongside its own figure’s more specific analogue listings and laboratory limits—not converted into an unequivocal chemical profile of every package.

This distinction is especially important when evaluating allegations about counterfeit or mislabeled CBD products. A marketing description, manufacturer’s ingredient list, measured sample from an allegedly identical product, and authenticated sealed exhibit from the actual patient are different levels of evidence. A full evidentiary examination could require lot identification, retention samples, seizure provenance, confirmatory product chemistry, metabolite identity, and case-specific toxicology.

Does Case 5 prove that pure CBD converts into THC inside a human body?

No. Cases 4 and 5 reported exposure to the same e-cigarette, yet Case 4’s screen and reported serum/urine THC-COOH were negative whereas Case 5 had a positive screen, serum THC-COOH of 10.8 ng/mL, and urine THC-COOH of 6.3 ng/mL. The product itself was unavailable, prior exposures were not experimentally excluded, and individual absorbed doses were not measured. Those facts do not identify a biochemical conversion pathway.

The discussion raised CBD-to-THC conversion as a hypothesis but also acknowledged experimental evidence against meaningful in-vivo conversion and distinguished chemical transformations outside the body under special conditions. The case series did not administer analytically verified pure CBD under controlled conditions, quantify CBD and THC metabolites before and after exposure, or perform a kinetic conversion experiment. It therefore does not prove that pure CBD became delta-9-THC in either person.

Alternative explanations—misidentified products, analogue content, different amounts inhaled, differing testing intervals, assay cross-reactivity, and earlier exposures—were not excluded. A sound report must distinguish demonstrated measurements from interpretations the original design cannot resolve.

Can a qualitative urine result identify a specific cannabinoid analogue?

Not without knowing exactly what that particular test recognizes. Immunoassays respond to their antibody and calibration chemistry; the appearance of a THC-positive result can depend on which metabolites or structurally related compounds cross-react. Conversely, a negative result can reflect insufficient analyte for the cutoff, specimen timing, a different target compound, or an analytic limitation. A bedside result does not produce the molecular specificity of a sufficiently validated targeted chromatography–mass-spectrometry method.

The Maki report names DS10 but does not provide complete target-specific interference studies for HHCP, H4CBD, THCV, or other analogues. It also does not give instrument traces or identification ions for each patient sample. It is therefore inappropriate to decide, solely from the screen, which listed cannabinoid a patient inhaled or which metabolite generated the response.

The site’s published confirmatory drug testing overview describes the distinction between preliminary screening and analytically specific identification. In litigation, the laboratory’s actual method, intended cutoff, validated cross-reactivity, reference standards, calibration, and quality-control records remain decisive.

What does the motorcycle episode in Case 3 prove?

The 18-year-old in Case 3 reported inhaling an e-cigarette product roughly six hours before a motorcycle incident involving a guardrail and fall. The source records nausea, a vague memory of the event, a positive DS10 THC screening result, serum THC-COOH of 9.2 ng/mL on day 1, and urine THC-COOH of 7 ng/mL. These are important clinical and toxicological observations.

They do not establish the specific mechanism of the crash. The paper does not present measured whole-blood active THC at the crash time, scene reconstruction, speed, vehicle condition, independent witness accounts, validated riding-performance measures, or a differential evaluation of other plausible causes. It also does not prove that the listed product constituents produced the concentrations observed, or whether the patient’s vague recollection arose from cannabinoid exposure, trauma, or another factor.

A court may need to evaluate exposure, effects, collision mechanics, and injury causation separately. The temporal sequence and positive metabolite findings warrant investigation, but they are not a quantitative reconstruction of individual psychomotor impairment.

Does the series support a fixed post-exposure waiting time for urine screening?

No universal fixed period follows from these five cases. The study’s discussion proposes that a screen obtained about an hour after exposure might precede sufficient urinary metabolite accumulation, drawing on external pharmacokinetic literature. However, it did not perform serial DS10 urine tests to show conversion from negative to positive in Case 2. Its follow-up concentrations in that patient were serum THC-COOH, not delayed DS10 urine outcomes.

Case 2’s serum sequence (5.5, 5.2, 3.9, and 4.2 ng/mL over four reported hospital days) should not be treated as a simple monotonic elimination experiment or translated into elapsed time since last use. Forensic interpretation would need actual blood-draw times, specimen handling, assay performance, possible subsequent exposure, and pharmacokinetic context. No individual half-life or back-extrapolated concentration was validated in this paper.

A repeat sample may be clinically indicated depending on the question, but the source does not establish when every urine assay must turn positive, or how a negative result should be interpreted without knowing the analytical cutoff and substance.

What can emergency symptoms establish about intoxication?

Nausea, vomiting, agitation, difficulty responding, and shortness of breath can accompany a variety of exposures or medical problems. Their observation matters, but none is chemically specific for active THC. This was not a blinded cannabis challenge study and did not include a standardized neurobehavioral battery, baseline laboratory function, a nonexposed comparison cohort, or an individualized concentration-response model.

Case 2’s reported unresponsiveness was observed before ambulance treatment and a negative urine DS10, while the serum metabolite was later reported. Case 4 had agitation and discomfort without detectable serum or urine THC-COOH; Case 5 was positive after ostensibly similar shared-device exposure. These contrasts are reasons to preserve clinical differential diagnosis, not to attribute each symptom to a single molecule on label evidence alone.

Proper testimony distinguishes what was reported by the patient, what hospital personnel observed, and what the laboratory measured. A named syndrome, psychiatric diagnosis, diminished legal capacity, or contemporaneous driving impairment would require additional evidence.

Which records would improve a forensic assessment of a CBD-product emergency visit?

The case series illustrates why an expert should obtain the original medical chart, arrival and symptom times, specimen-collection timestamps, actual laboratory reports rather than a secondary summary, and any detailed product history or exhibit. The information should identify whether the specimen was whole blood, clotted serum, plasma, or urine and whether the result reflected a qualitative screen, confirmatory identity, or quantitative concentration. Treatment and collection can occur at different times, so a general “hospital arrival” timestamp is inadequate for every inference.

For an alleged labeled product, chain of custody and chemical characterization matter as much as a photograph or marketing claim. The analytical request should distinguish delta-9-THC, delta-8-THC, THCV, HHC-related compounds, and specific metabolites; different instruments and reference libraries may cover different targets. A broad cannabinoid class signal is not sufficient to assign an exact ingredient without method-specific confirmation.

The site’s published specimen-collection guide addresses the prerequisites of appropriate sampling, labeling, handling, and preservation. In a contested matter, the full case record and quality system—not a generalized reference article—must control case-specific conclusions.

What distinguishes this evidence from an impairment study or a test-validation study?

The design was a descriptive case series of five selected emergency presentations. It had no planned dosing, no assigned CBD or THC group, no controlled product source, no untreated comparator, no predeclared driving endpoint, and no complete paired blood-and-urine protocol. The analyte denominators vary because not every person had every sample tested. This is why five observed DS10 outcomes cannot be used as a diagnostic-performance denominator with known true exposure status for each patient.

The report supplies observed clinical circumstances and a set of molecular findings valuable for generating targeted hypotheses. It does not establish a product-market contamination prevalence, a rate of conversion of CBD into THC, a validated metabolite-based intoxication threshold, or a probability that the motorbike incident was caused by cannabinoids. These are different research questions requiring purpose-built designs.

The especially useful forensic takeaway is that one negative rapid urine cannabinoid screen is not a comprehensive chemical certificate of nonexposure. The converse is equally important: a positive screen or a serum THC-COOH value does not establish the exposure route, psychoactive dose, or impaired conduct of an individual.

Frequently asked forensic questions

1. Can a negative DS10 urine test rule out all exposure to cannabinoids?

No. It reports a screening result for the analytes and thresholds to which that device responds at the tested time. In Case 2 the urine screen was negative while serum THC-COOH was detected. Without a urine confirmatory result from that same patient, the observation does not quantify the false-negative rate of DS10.

2. How many of the five patients had positive urine screens?

Cases 3 and 5 were marked THC positive on DS10; Cases 1, 2, and 4 were recorded as negative. That is two positives out of five tests in a selected case series, not a prevalence estimate for CBD-product users.

3. What did the reported 5.5, 9.2, and 10.8 ng/mL values measure?

They were day-1 serum THC-COOH values for Cases 2, 3, and 5 respectively. They were not active delta-9-THC concentrations in forensic venous whole blood, and do not support direct comparisons with such cutoffs.

4. Did the authors prove the products had a measured delta-9-THC concentration?

No complete batch-specific quantitative delta-9-THC product analyses are reported. Product figures identify or list cannabinoid components and analogues for three products, while the device used in Cases 4 and 5 was unavailable for comparable inspection. Product identity needs its own validated analytical record.

5. Does Case 5 demonstrate chemical conversion of pure CBD into THC?

No. The product was not independently established as pure CBD, and prior exposure, batch contents, dose, and assay specificity were not controlled. The conversion explanation is a hypothesis discussed by the authors, not a pathway proven by these cases.

6. Does Case 3 establish cannabis-related motorcycle impairment?

No. Although a motorcycle fall occurred after reported product use and the patient had a positive screen and metabolite results, the study did not measure active THC at the event or establish a driver-performance or collision-causation model.

7. What is the best next analytical question when urine screening and serum chemistry differ?

Ask which precise analyte, method, matrix, threshold, collection time, and validation record underlie each result. Then determine whether the apparent discrepancy arises from a real analytical disagreement or from tests that simply answer different questions. A targeted, method-appropriate confirmation may help; an assumed universal waiting period or serum-to-whole-blood conversion does not.

Primary source and scope of the conclusion

Maki Y, Tsuchiya A, Yamamoto R, Saito T, Morita S, Nakagawa Y. Safety of cannabidiol products as a social issue: A case series. Acute Medicine & Surgery. 2024;11:e965. Original complete five-page case report: https://doi.org/10.1002/ams2.965. The evidence is five selected 2023 emergency presentations, with patient-specific missing specimens and no controlled pure-CBD exposure. The report supports matrix- and method-specific investigation; it cannot identify an individual’s contemporaneous active THC concentration, prove CBD conversion, or assign a particular accident or symptom to one substance without additional case evidence.